Business & FinanceTop StoryTop StoryLatest News
Mankind Pharma Q2 PAT Rises 37.7% on Strong Domestic Chronic Business
Sentiment: PositiveHigh Priority
What Happened?
Mankind Pharma reported a 37.7% year-on-year increase in consolidated net profit for Q2 FY27, reaching ₹716 crore, driven by strong domestic demand for chronic drugs. Revenue rose 17.3% to ₹4,338 crore.
Key points
- Mankind Pharma's profit after tax (PAT) increased to ₹716 crore from ₹520 crore year-on-year.
- Revenue from operations grew 17.3% year-on-year to ₹4,338 crore.
- Domestic business contributed 86% to overall revenue, growing 14.8% to ₹3,657 crore.
- The company's OTC consumer healthcare business saw only 1.2% growth due to industry-wide slowdowns.
- International revenue rose by 33% to ₹2,061 crore, supported by Mankind and BSV International.
- The acquisition of Armed Cell Therapeutics enhances R&D capabilities for CAR-T therapies.
Key insights
- The growth in chronic therapies may lead to increased market competition among pharmaceutical companies.
- Mankind's focus on R&D could position it favorably in the evolving CAR-T therapy market.
- The muted growth in OTC products highlights potential challenges in consumer healthcare segments.
Market Impact
Pharmaceuticals
PositiveThe strong performance in chronic drug sales could positively influence the pharmaceutical sector's growth.
Why it matters
The strong growth in Mankind Pharma's profits indicates robust demand for chronic medications in India.
Tags
Entities
Mankind Pharma· CompanyBharat Serums and Vaccines· CompanyIndia· Country
Source
Business Standard
